• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Reimbursement Achievable for Biologics in Psoriasis


The January FDA clearance of Biogen Inc.'s Amevive (alefacept) for thetreatment of moderate-to-severe chronic plaque psoriasis officially usheredin the era of biologic treatments for dermatologists. Amgen Inc.'s biologic,Enbrel (etanercept), FDA-cleared for treating psoriatic arthritis, has alsobeen prescribed (off-label) for psoriasis. Amevive, administered by IM injectionor IV infusion in the physician's office, is purchased directly from Biogenby the physician or institution while self-injected Enbrel is purchasedby the patient at the pharmacy.

Related Videos
Dr. Suneel Chilukuri
 Health Care Impacts on Gender and Sexual Minority Patients
 Caring for Gender and Sexual Minority Patients
© 2024 MJH Life Sciences

All rights reserved.